Related Experiment Video
Updated: Sep 14, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Factor V Leiden mutation in Sneddon syndrome
Insights
Sneddon syndrome (SNS) patients with antiphospholipid antibodies (aPL) negative status show a higher prevalence of the factor V Leiden mutation. This suggests factor V Leiden mutation may contribute to aPL-negative SNS, highlighting the condition
Area of Science:
- Vascular Neurology
- Hematology
- Genetics
Background:
- Sneddon syndrome (SNS) is defined by ischemic cerebrovascular events and livedo racemosa.
- The underlying pathophysiology of SNS remains incompletely understood.
- Antiphospholipid antibodies (aPL) are implicated in some cases of SNS.
Purpose of the Study:
- To investigate the prevalence of the factor V Leiden mutation in patients with Sneddon syndrome.
- To assess the association between factor V Leiden mutation and antiphospholipid antibody (aPL) status in SNS patients.
Main Methods:
- Fifty-three Caucasian patients diagnosed with SNS were analyzed.
- Factor V Leiden mutation was detected using direct genomic analysis.
- Antiphospholipid antibodies (aPL) were assessed through multiple determinations.
Main Results:
- The factor V Leiden mutation was identified in 11.3% of all SNS patients, all heterozygous.
- The mutation's frequency was significantly higher in aPL-negative SNS patients (19.3%) compared to aPL-positive patients (0%; P = 0.035).
- No significant differences in clinical data or thrombosis history were observed between aPL-negative SNS patients with or without the factor V Leiden mutation.
Conclusions:
- A notable prevalence of heterozygous factor V Leiden mutation was found in aPL-negative SNS patients.
- This finding supports the concept of Sneddon syndrome being a heterogeneous condition.
- Factor V Leiden mutation may play a role in the pathogenesis of aPL-negative Sneddon syndrome.
Abstract:
Sneddon syndrome (SNS) is characterized by the association of ischaemic cerebrovascular events and widespread livedo racemosa. Its pathophysiology is still controversial. The aim of this study was to evaluate the prevalence of factor V Leiden mutation in consecutive patients referred for SNS according to antiphospholipid antibodies (aPL) status. Fifty-three Caucasian patients were enrolled from 1996 to 2001. Diagnosis of SNS was based on the presence of a widespread livedo racemosa and at least one clinical neurologic ischaemic event. The following investigations were performed: detection of antithrombin III, protein C and protein S deficiency, lupus anticoagulant, anticardiolipin and anti-beta2 glycoprotein I antibodies, biologic false-positive test for syphilis, and factor V Leiden mutation by direct genomic analysis. Fisher's test and t-test were used for statistics. Detection of aPL on multiple determinations was negative in 31 patients (group 1) and positive in 22 patients (group 2). Factor V Leiden mutation was detected in six patients (11.3%), heterozygous in all. The frequency of this mutation was statistically higher in group 1 (6/31, 19.3%) than in group 2 (0/22; P = 0.035). Within aPL-negative SNS, the comparison of patients with versus without factor V Leiden mutation showed no difference for clinical data or familial history of thrombosis. A high prevalence of heterozygous factor V mutation was found in aPL-negative patients with SNS. This finding adds further arguments to consider SNS as a heterogeneous entity.
Related Concept Videos
Genetic Lingo
Pleiotropy
Sex-linked Disorders
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...

